Yesterday I started digging in to Matt McCall’s tease about a huge opportunity in Chinese biotech… and, as promised, today I’m finishing the job. The basic premise is that China is pushing to make biopharma a bigger part of its economy in both the current five-year plan and the “made in China 2025” plan, and […]
Articles
Matt McCall’s out with another high-priced promo letter that promises the potential for huge gains — this time, by finding the stocks that he thinks will benefit from China’s massive increase in health care spending in the years to come. The ad is for his Early Stage Investor, and he claims to be making a […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
I have lived in China for years and belief in the Biotech story on the long run. To boost the sector the HKSE (Hongkong ...
The issue I take with $CHNA is that it has $7 Million in assets. If it closes down (which it might) you receive a check ...
KURE is another ETF choice, quite similar to CHNA but a bit lower expense ratio: 0.65% vs 0.79%...